Cargando…

EGFR Monoclonal Antibodies in the Treatment of Squamous Cell Carcinoma of the Head and Neck: A View beyond Cetuximab

Squamous cell carcinoma of the head and neck (SCCHN) is a prevalent disease both in the United States and worldwide with an overall poor prognosis, in part due to limited activity of existing therapy. Primary therapy is largely dictated by the anatomical origin of the cancer and whether distant dise...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kono, Scott A., Haigentz, Missak, Yom, Sue S., Saba, Nabil
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Hindawi Publishing Corporation 2012
Materias:	Review Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3465896/ https://www.ncbi.nlm.nih.gov/pubmed/23056941 http://dx.doi.org/10.1155/2012/901320

Ejemplares similares

Monoclonal Antibodies against Epidermal Growth Factor Receptor in Solid Tumors
por: Saba, Nabil F., et al.
Publicado: (2012)

Dermatologic Toxicities from Monoclonal Antibodies and Tyrosine Kinase Inhibitors against EGFR: Pathophysiology and Management
por: Abdullah, Shaad E., et al.
Publicado: (2012)

Response assessment after induction chemotherapy for head and neck squamous cell carcinoma: From physical examination to modern imaging techniques and beyond
por: de Bree, Remco, et al.
Publicado: (2017)

The Current Role of Salvage Surgery in Recurrent Head and Neck Squamous Cell Carcinoma
por: Hamoir, Marc, et al.
Publicado: (2018)

Commentary: Randomized Phase II Study of Duligotuzumab (MEHD7945A) vs. Cetuximab in Squamous Cell Carcinoma of the Head and Neck (MEHGAN Study)
por: Saba, Nabil F.
Publicado: (2017)

FOXD1 Regulates the Sensitivity of Cetuximab by Regulating the Expression of EGFR in Head and Neck Squamous Cell Cancer
por: Mu, Lan, et al.
Publicado: (2022)

EGFR Inhibition by Cetuximab Modulates Hypoxia and IFN Response Genes in Head and Neck Squamous Cell Carcinoma
por: Chaudhary, Ritu, et al.
Publicado: (2023)

Aberrant HER3 ligand heregulin-expressing head and neck squamous cell carcinoma is resistant to anti-EGFR antibody cetuximab, but not second-generation EGFR-TKI
por: Yonesaka, Kimio, et al.
Publicado: (2019)

Antiepidermal Growth Factor Receptor Therapy in Squamous Cell Carcinoma of the Head and Neck
por: Shaib, Walid, et al.
Publicado: (2012)

Retracted: FOXD1 Regulates the Sensitivity of Cetuximab by Regulating the Expression of EGFR in Head and Neck Squamous Cell Cancer
por: Healthcare Engineering, Journal of
Publicado: (2023)

Review of cetuximab in the treatment of squamous cell carcinoma of the head and neck
por: Merlano, Marco, et al.
Publicado: (2007)

Current Aspects and Future Considerations of EGFR Inhibition in Locally Advanced and Recurrent Metastatic Squamous Cell Carcinoma of the Head and Neck
por: Patel, Bhamini, et al.
Publicado: (2021)

Safety and Efficacy of MEDI0457 plus Durvalumab in Patients with Human Papillomavirus–Associated Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma
por: Aggarwal, Charu, et al.
Publicado: (2023)

Cetuximab Rechallenge and Monotherapy in Patients with Squamous Cell Carcinoma of the Head and Neck
por: Knutzen, Greg, et al.
Publicado: (2015)

Biomarkers of cetuximab resistance in patients with head and neck squamous cell carcinoma
por: Leblanc, Olivia, et al.
Publicado: (2020)

The Tumour Suppressor CYLD Is Required for Clathrin-Mediated Endocytosis of EGFR and Cetuximab-Induced Apoptosis in Head and Neck Squamous Cell Carcinoma
por: Liu, Rin, et al.
Publicado: (2021)

Anti-EGFR monoclonal antibody Cetuximab displays potential anti-cancer activities in feline oral squamous cell carcinoma cell lines
por: Altamura, Gennaro, et al.
Publicado: (2022)

Recent results of cetuximab use in the treatment of squamous cell carcinoma of the head and neck
por: Perri, Francesco, et al.
Publicado: (2009)

Efficacy of gemcitabine and cetuximab combination treatment in head and neck squamous cell carcinoma
por: MASEKI, SHINICHIRO, et al.
Publicado: (2013)

Phase II Trial of CDX-3379 and Cetuximab in Recurrent/Metastatic, HPV-Negative, Cetuximab-Resistant Head and Neck Cancer
por: Bauman, Julie E., et al.
Publicado: (2022)

Concurrent Cetuximab and Nivolumab as a Second-Line or beyond Treatment of Patients with Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma: Results of Phase I/II Study
por: Chung, Christine H., et al.
Publicado: (2021)

Characterization of 7A7, an anti-mouse EGFR monoclonal antibody proposed to be the mouse equivalent of cetuximab
por: He, Xuzhi, et al.
Publicado: (2018)

Aurora Kinase Inhibition Overcomes Cetuximab Resistance in Squamous Cell Cancer of the Head and Neck
por: Hoellein, Alexander, et al.
Publicado: (2011)

EGFR Alterations Influence the Cetuximab Treatment Response and c-MET Tyrosine-Kinase Inhibitor Sensitivity in Experimental Head and Neck Squamous Cell Carcinomas
por: Nelhűbel, Györgyi A., et al.
Publicado: (2021)

TLR3 agonists improve the immunostimulatory potential of cetuximab against EGFR(+) head and neck cancer cells
por: Ming Lim, Chwee, et al.
Publicado: (2013)

Novel EGFR ectodomain mutations associated with ligand-independent activation and cetuximab resistance in head and neck cancer
por: Nair, Sindhu, et al.
Publicado: (2020)

Targeting EGFR and HER-2 with cetuximab- and trastuzumab-mediated immunotherapy in oesophageal squamous cell carcinoma
por: Kawaguchi, Y, et al.
Publicado: (2007)

T cell repertoire in peripheral blood as a potential biomarker for predicting response to concurrent cetuximab and nivolumab in head and neck squamous cell carcinoma
por: Wang, Xuefeng, et al.
Publicado: (2022)

EGFR Mutations in Head and Neck Squamous Cell Carcinoma
por: Nair, Sindhu, et al.
Publicado: (2022)

Tumor-Specific Antibody, Cetuximab, Enhances the In Situ Vaccine Effect of Radiation in Immunologically Cold Head and Neck Squamous Cell Carcinoma
por: Jin, Won Jong, et al.
Publicado: (2020)

The hypoxic tumor microenvironment and drug resistance against EGFR inhibitors: preclinical study in cetuximab-sensitive head and neck squamous cell carcinoma cell lines
por: Boeckx, Carolien, et al.
Publicado: (2015)

Call for Adoption of Synchronized Biweekly Dosing of Anti-EGFR Agent Cetuximab: Implications for Patients with Metastatic Colorectal Cancer, and Squamous Cell Carcinoma of the Head and Neck
por: Kasi, Pashtoon Murtaza
Publicado: (2022)

A Phase 1b/2 Study of Alpelisib in Combination with Cetuximab in Patients with Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
por: Razak, Albiruni R. Abdul, et al.
Publicado: (2023)

Effects of Cetuximab and Erlotinib on the behaviour of cancer stem cells in head and neck squamous cell carcinoma
por: Setúbal Destro Rodrigues, Maria Fernanda, et al.
Publicado: (2018)

Weekly Docetaxel, Cisplatin, and Cetuximab in Palliative Treatment of Patients with Squamous Cell Carcinoma of the Head and Neck
por: Trieu, Vanessa, et al.
Publicado: (2018)

Cetuximab-Containing Combinations in Locally Advanced and Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
por: Taberna, Miren, et al.
Publicado: (2019)

The Use of Epidermal Growth Factor Receptor Monoclonal Antibodies in Squamous Cell Carcinoma of the Head and Neck
por: Russell, Jeffery S., et al.
Publicado: (2012)

EGFR R521K Polymorphism Is Not a Major Determinant of Clinical Cetuximab Resistance in Head and Neck Cancer
por: Cserepes, Mihály, et al.
Publicado: (2022)

Anti-EGFR targeted monoclonal antibody isotype influences anti-tumor immunity in head and neck cancer patients
por: Trivedi, Sumita, et al.
Publicado: (2015)

Simultaneous targeting of EGFR, HER2, and HER4 by afatinib overcomes intrinsic and acquired cetuximab resistance in head and neck squamous cell carcinoma cell lines
por: De Pauw, Ines, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_al0ndt4f7ck7206532psg75vas